首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Molecular Cancer Therapeutics

Molecular Cancer Therapeutics杂志,由American Association for Cancer Research Inc.出版,于2001年创刊,Monthly,出版语言English,ISSN:1535-7163,E-ISSN:1538-8514。

投稿咨询
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
6.9
CiteScore
9.5
期刊收录
SCI、SCIE

Molecular Cancer Therapeutics(中文译名:《分子癌症治疗》),ISSN:1535-7163,EISSN:1538-8514,是American Association for Cancer Research Inc.出版的国际性学术期刊,创刊于2001年,以Monthly形式稳定发行,2026年总发文量约154篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达6.9,2025年期刊CiteScore为9.5,2025年期刊自引率约1.4%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Molecular Cancer Therapeutics长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约3月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、England、Japan、GERMANY (FED REP GER)、South Korea、Netherlands等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMHARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、DANA-FARBER CANCER INSTITUTE、ASTRAZENECA、MEMORIAL SLOAN KETTERING CANCER CENTER、UNIVERSITY OF PENNSYLVANIA等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 55 / 333

83.6

学科:ONCOLOGY SCIE Q1 62 / 333

81.53

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 60 / 328

81.9

学科:ONCOLOGY SCIE Q1 62 / 328

81.25


中国学者近期发文

1
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profile

Author:Tian, Yunan; Zhang, Jieqiong; Sun, Xing; Yang, Changyong; Liao, Cheng

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 3, pp. 371-385. DOI: 10.1158/1535-7163.MCT-24-0680

2
Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistanc

Author:Pulido, Ines; Gunder, Laura C.; Ying, Chenghao; Wang, Yaya; Dai, Yan; Yang, Zimo; Rahnama, Alireza; Li, Jinhua; Sun, Yuetong; Liu, Chuhe; Zhou, Haoxin; Wang, Guoqiang; Foley, Kevin P.; Abdelhady, Khaled; Massad, Malek G.; Prince, Thomas L.; Papautsky, Ian; Ying, Weiwen; Shimamura, Takeshi

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 207-215. DOI: 10.1158/1535-7163.MCT-24-1173

3
SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumor

Author:Peng, Yani; Yang, Changyong; Dong, Liwei; Sun, Xing; Zheng, Wei; Gong, Yanling; Shi, Qing; Ji, Ping; Chen, Simeng; Zhang, Wei; Liao, Cheng

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 322-332. DOI: 10.1158/1535-7163.MCT-24-0752

4
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase-Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficac

Author:Niu, Dun; Zhang, Shaotong; Ma, Xiaozhuang; Wu, Yaran; Zhu, Junshi; Ran, Jianglang; Shan, Meihua; Dai, Xufang; Lu, Lu; Yang, Mingzhen; Lian, Jiqin

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 272-282. DOI: 10.1158/1535-7163.MCT-25-0356

5
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanis

Author:Zhang, Huan; He, Fufan; Cao, Lei; Ni, Haiqing; Li, Ninghuan; Liu, Yang; Wu, Min; Liu, Ya; Wu, Bing; Li, Li; Wu, Zhihai; Ling, Xiaomin; Zhou, Shuaixiang; Li, Yiming; Deng, Shuxuan; Wu, Weiwei; Chu, Qian

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 21-33. DOI: 10.1158/1535-7163.MCT-25-0425

6
Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradatio

Author:Wang, Han; Luo, Yuxuan; Artham, Sandeep; Wang, Qianqian; Peng, Yi; Yun, Zixi; Li, Xinyue; Wu, Chen; Liu, Zhenghao; Weber-Bonk, Kristen L.; Pai, Chun-Peng; Cao, Yuan; Yue, Jiangan; Park, Sunghee; Keri, Ruth A.; Geng, Lisheng; Mcdonnell, Donald P.; Kao, Hung-Ying; Yang, Sichun

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 107-124. DOI: 10.1158/1535-7163.MCT-25-0405

7
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Model

Author:Lu, Shan; Pan, Xiao; Volckova, Eva; Shinde, Anjali; Fuller, Schuyler R.; Egan, Regina; Ma, Jianli; Kung, Jong; Ott, Christopher J.; Hata, Aaron N.; Benes, Cyril H.; Kang, Jing X.; Willers, Henning

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 6, pp. 920-930. DOI: 10.1158/1535-7163.MCT-24-0213

8
NOC2L Promotes Paclitaxel Resistance in Various Types of Ovarian Cancers by Decreasing NDUFA4 through Histone Acetylation Suppressio

Author:Gu, Hao; Qi, Suwan; Chen, Jiaying; Wu, Hongqin; Xu, Jianjuan; Feng, Yaling

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 6, pp. 942-956. DOI: 10.1158/1535-7163.MCT-24-0512

9
First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosi

Author:Zhang, Wenjie; Wang, Jing; Shi, Wei; Qiu, Hu; Ke, Shaobo; Tian, Yuanyuan; Gong, Yi; Zhang, Caiyutian; Chen, Jiamei; Wu, Yong; Zhao, Wensi; Chen, Yongshun

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 5, pp. 720-727. DOI: 10.1158/1535-7163.MCT-24-0143

10
Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunit

Author:Lin, Yuan; Lin, Kan; Fu, Qiang; Sun, Xing; Wang, Huan; Su, Lu; Xu, Yanhui; Liao, Cheng

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 5, pp. 664-677. DOI: 10.1158/1535-7163.MCT-23-0614


在线咨询

Molecular Cancer Therapeutics

国际简称:MOL CANCER THER参考译名:分子癌症治疗

年发文量:154 CiteScore:9.5 是否预警:否 Gold OA文章占比:36.23% 研究类文章占比:91.56%

杂志社联系方式:AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404

Molecular Cancer Therapeutics